LIGAND PHARMACEUTICALS INC (LGND) — insider trading
Health Care · NASDAQ
LIGAND PHARMACEUTICALS INC (LGND) has 41 reported SEC Form 4 insider transactions in our data, including 17 open-market sales among the most recent 41 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion (derivative) | 5,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 600 | $317.15 | $190.3K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 900 | $315.78 | $284.2K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 100 | $314.58 | $31.5K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 700 | $313.46 | $219.4K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,081 | $312.28 | $337.6K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 1,119 | $311.72 | $348.8K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 104 | $310.20 | $32.3K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Open-market sale | 396 | $308.99 | $122.4K | Form 4 |
| 2026-07-01 | Reardon Andrew | Officer (CLO & Secretary) | Option exercise / conversion | 5,000 | $52.27 | $261.4K | Form 4 |
| 2026-06-30 | Davis Todd C | Director, Officer (Chief Executive Officer) | Other acquisition or disposition | 132 | $160.71 | $21.2K | Form 4 |
| 2026-06-30 | Espinoza Octavio | Officer (Chief Financial Officer) | Other acquisition or disposition | 17 | $160.71 | $2.7K | Form 4 |
| 2026-06-30 | Reardon Andrew | Officer (CLO & Secretary) | Other acquisition or disposition | 132 | $160.71 | $21.2K | Form 4 |
| 2026-06-16 | Sabba Stephen L | Director | Option exercise / conversion (derivative) | 2,145 | $0.00 | $0 | Form 4 |
| 2026-06-16 | Sabba Stephen L | Director | Open-market sale | 2,145 | $254.00 | $544.8K | Form 4 |
| 2026-06-16 | Sabba Stephen L | Director | Option exercise / conversion | 2,145 | $66.13 | $141.8K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion (derivative) | 1,000 | $0.00 | $0 | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion (derivative) | 3,000 | $0.00 | $0 | Form 4 |
| 2026-06-12 | Haas Jason | Director | Open-market sale | 3,461 | $256.08 | $886.3K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Open-market sale | 3,000 | $255.01 | $765.0K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion | 1,000 | $51.56 | $51.6K | Form 4 |
| 2026-06-12 | Haas Jason | Director | Option exercise / conversion | 3,000 | $51.56 | $154.7K | Form 4 |
| 2026-06-11 | Aryeh Jason | Director | Open-market sale | 4,500 | $250.00 | $1.13M | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 3,405 | $251.62 | $856.8K | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 697 | $249.53 | $173.9K | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 232 | $248.11 | $57.6K | Form 4 |
| 2026-06-10 | LAMATTINA JOHN L | Director | Open-market sale | 257 | $247.22 | $63.5K | Form 4 |
| 2026-06-10 | Aryeh Jason | Director | Open-market sale | 500 | $250.00 | $125.0K | Form 4 |
| 2026-06-05 | Aryeh Jason | Director | Grant / award / vesting (derivative) | 2,938 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Aryeh Jason | Director | Grant / award / vesting | 836 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Haas Jason | Director | Grant / award / vesting (derivative) | 2,938 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Haas Jason | Director | Grant / award / vesting | 836 | $0.00 | $0 | Form 4 |
| 2026-06-05 | KOZARICH JOHN W | Director | Grant / award / vesting (derivative) | 2,938 | $0.00 | $0 | Form 4 |
| 2026-06-05 | KOZARICH JOHN W | Director | Grant / award / vesting | 836 | $0.00 | $0 | Form 4 |
| 2026-06-05 | LAMATTINA JOHN L | Director | Grant / award / vesting (derivative) | 2,938 | $0.00 | $0 | Form 4 |
| 2026-06-05 | LAMATTINA JOHN L | Director | Grant / award / vesting | 836 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Sabba Stephen L | Director | Grant / award / vesting (derivative) | 2,938 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Sabba Stephen L | Director | Grant / award / vesting | 836 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Zimmermann Martine | Director | Grant / award / vesting (derivative) | 2,938 | $0.00 | $0 | Form 4 |
| 2026-06-05 | Zimmermann Martine | Director | Shares withheld for taxes / exercise cost | 182 | $237.00 | $43.1K | Form 4 |
| 2026-06-05 | Zimmermann Martine | Director | Grant / award / vesting | 836 | $0.00 | $0 | Form 4 |
Ask the chat about LGND's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: LIGAND PHARMACEUTICALS INC (LGND).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.